论文部分内容阅读
目的观察参芪扶正注射液对老年非小细胞肺癌 (NSCLC)化疗的影响。方法 1 2 0例老年NSCLC患者均采用NP方案化疗 ,其中治疗组 60例化疗前 1周开始加用参芪扶正注射液。观察两组近期疗效、远期生存率、化疗后生活质量评价、血液毒性反应及免疫功能变化情况。结果两组近期疗效及 1、2年生存率比较差异无显著性 (P >0 .0 5 ) ,但 3年生存率治疗组为 4 5 7%,对照组为 1 9 4 %,前者高于后者(P <0 0 5 ) ;化疗后患者生活质量评价治疗组优于对照组 (P <0 .0 5 )。此外 ,治疗组化疗后血液毒性反应、明显低于对照组 ,差异有显著性 (P <0 .0 5 ) ;免疫功能与治疗前比较差异无显著性 (P >0 0 5 )。结论参芪扶正注射液对老年NSCLC化疗有一定减毒作用。
Objective To observe the effect of Shenqi Fuzheng injection on the chemotherapy of elderly non-small cell lung cancer (NSCLC). Methods One hundred and twenty elderly NSCLC patients were treated with NP regimen, of which 60 cases in the treatment group started to add Shenqi Fuzheng injection one week before chemotherapy. The curative effect, long-term survival rate, quality of life after chemotherapy, hematological toxicity and immune function were observed. Results There was no significant difference between the two groups in short-term efficacy and in 1-year and 2-year survival rates (P> 0.05), but the 3-year survival rate was 45.7% in the treatment group and 1.94% in the control group, The latter (P <0.05). The quality of life after chemotherapy in the treatment group was better than that in the control group (P <0.05). In addition, the hematological toxicity in the treatment group after chemotherapy was significantly lower than that in the control group (P <0.05). There was no significant difference in the immune function between before and after treatment (P> 0.05). Conclusion Shenqi Fuzheng injection can attenuate NSCLC chemotherapy in elderly patients.